A GHRH (1-29) analog — the shortest fully active fragment of GHRH — historically used clinically as a diagnostic agent and studied for supporting endogenous growth-hormone output.
Mechanism under study
Stimulates the pituitary GHRH receptor to promote natural, pulsatile growth-hormone secretion, preserving feedback regulation.
Research-reported dosing
Research references commonly cite ~100–300 mcg, often pre-sleep to align with natural GH pulses. Historical clinical use was as a diagnostic agent.
5 mg vial + 2 mL bacteriostatic water = 2500 mcg/mL.
A 300 mcg dose ≈ 12 units (25 mcg per unit).
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Sermorelin comparisons
Sermorelin FAQ
What is Sermorelin?
A GHRH (1-29) analog — the shortest fully active fragment of GHRH — historically used clinically as a diagnostic agent and studied for supporting endogenous growth-hormone output.
What is the half-life of Sermorelin?
Short — roughly 10–20 minutes.
What is the research-reported dosing for Sermorelin?
Research references commonly cite ~100–300 mcg, often pre-sleep to align with natural GH pulses. Historical clinical use was as a diagnostic agent.
How is Sermorelin reconstituted?
5 mg vial + 2 mL bacteriostatic water = 2500 mcg/mL.
Is Sermorelin FDA-approved?
No — Sermorelin is not FDA-approved and is sold for laboratory research use only.
References
Guides featuring Sermorelin
Related peptides
CJC-1295
Growth-hormone-releasing hormone (GHRH) analog
A synthetic GHRH analog studied for stimulating growth-hormone release. Exists in a short-acting 'no-DAC' form (modified GRF 1-29) and a long-acting 'DAC' form.
Ipamorelin
Ghrelin-receptor agonist (GH secretagogue)
A selective ghrelin-receptor agonist studied for stimulating growth-hormone release with comparatively little effect on cortisol or prolactin, making it a frequently referenced 'clean' secretagogue.
Tesamorelin
Stabilized GHRH analog
A stabilized GHRH analog that is FDA-approved (as Egrifta) to reduce excess visceral adipose tissue in HIV-associated lipodystrophy — one of the few peptides in this index with an approved human indication.